---
title: "Enveda’s ENV-308: Early Phase 1 data on a pill that aims to mimic exercise and preserve lean mass"
id: "stat-news-0-stat-a-pill-that-mimics-exercise-early-results-on-drug-designed-to-maintain"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-a-pill-that-mimics-exercise-early-results-on-drug-designed-to-maintain"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/08/18/enveda-pill-mimics-exercise-phase-one-trial-leptin-weight-loss-maintenance/?utm_campaign=rss"
published_at: "2026-08-18T10:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Enveda’s ENV-308: Early Phase 1 data on a pill that aims to mimic exercise and preserve lean mass
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-a-pill-that-mimics-exercise-early-results-on-drug-designed-to-maintain
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/08/18/enveda-pill-mimics-exercise-phase-one-trial-leptin-weight-loss-maintenance/?utm_campaign=rss)
- **Published At:** 2026-08-18T10:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Enveda, a five-year-old biotech in Boulder, Colorado, announced Phase 1 results for **ENV-308**, an oral drug candidate designed to mimic an exercise-related metabolite called **lactate phenylalanine (lac‑phe)**. - Lac‑phe was identified by Stanford researchers and reported in a 2022 Nature paper to suppress appetite and reduce obesity in animal models; Enveda chemically engineered a compound intended to reproduce those effects orally. - ENV-308 is described by the company as acting on **leptin** signaling; Enveda calls it a potential first “**leptin sensitizer in a pill**.” - The company positions the candidate as a way to help maintain weight loss while preserving **lean muscle mass**, addressing concerns about muscle loss when people stop and restart GLP‑1 drugs. - Enveda also highlights the goal of avoiding the common **gastrointestinal side effects** that accompany GLP‑1 therapies. - The Phase 1 results were released in a company press release; detailed efficacy, safety data, trial design, participant numbers, and outcomes were not reported in the source article. - The reporting is by STAT’s Elizabeth Cooney (Cardiovascular Disease Reporter); additional content in the original article is behind STAT+ subscription access. - Key context: the concept is to reproduce one component of exercise biology pharmacologically—appetite suppression and lean mass preservation—based on lac‑phe biology rather than on GLP‑1 receptor agonism.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/08/18/enveda-pill-mimics-exercise-phase-one-trial-leptin-weight-loss-maintenance/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/18/enveda-pill-mimics-exercise-phase-one-trial-leptin-weight-loss-maintenance/?utm_campaign=rss) [legal](https://www.statnews.com/topic/legal/) [research](https://www.statnews.com/topic/research/) [Cancer](https://www.statnews.com/topic/cancer/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Exclusive](https://www.statnews.com/category/exclusive/) # A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass ## Enveda says Phase 1 trial shows compound has promise as ‘leptin sensitizer in a pill’ * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/18/enveda-pill-mimics-exercise-phase-one-trial-leptin-weight-loss-maintenance/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/08/LongLab_Immunofluorescence-of-the-biosynthetic-enzyme-for-exercise-inducible-Lac-Phe-Cndp2-green-and-nuclei-DAPI-blue-in-mouse-gut-645x645.jpg) The lactate phenylalanine biosynthetic enzyme, a molecule released after exercise that Enveda has chemically engineered into an oral drug candidate to mimic its effects on appetite and weight.Jan Spaas/Stanford ![](https://www.statnews.com/wp-content/uploads/2021/02/liz-c-avatar-small2-80x80.png) By [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) Aug. 18, 2026 Cardiovascular Disease Reporter ![](https://www.statnews.com/wp-content/uploads/2021/02/liz-c-avatar-small2-80x80.png) [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) 1. [](https://x.com/cooney_liz "X") elizabeth.cooney@statnews.com Liz covers cardiovascular and metabolic disease, asking [why we’re not doing better](https://www.statnews.com/2024/10/15/cardiovascular-disease-rising-experts-on-causes/) or even [losing ground](https://www.statnews.com/2024/04/24/heart-failure-deaths-decline-undone/) against the world’s leading killer. Send tips on Signal at LizC.22. If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you might call it exercise in a pill. Now a company is releasing early results for a compound to do just that. The pill, the company hopes, can maintain weight loss without the common gastrointestinal effects of GLP-1s. The component of exercise it is designed to re-create is preservation of lean muscle mass, a concern when people yo-yo on and off GLP-1 drugs, losing more muscle each time. Advertisement Enveda, a 5-year-old biotech based in Boulder, Colo., announced Phase 1 results in a press release Tuesday for an oral drug candidate that imitates lactate phenylalanine (lac-phe for short), a small molecule metabolite discovered by Stanford scientists. Those researchers showed in a [2022 Nature paper](https://www.nature.com/articles/s41586-022-04828-5) that lac-phe can suppress appetite and lower obesity in animals. Lac-phe and ENV-308, Enveda’s chemically engineered version, both act on leptin, a hormone that has been the target of scientists and drug developers for decades. If confirmed in clinical trials, the company says, ENV-308 would be the first “leptin sensitizer in a pill.” STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotech](https://www.statnews.com/topic/biotech/), [cardiovascular disease](https://www.statnews.com/topic/cardiovascular-disease/), [chronic diseases](https://www.statnews.com/topic/chronic-diseases/), [drug development](https://www.statnews.com/topic/drug-development/), [Obesity](https://www.statnews.com/topic/obesity/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/liz-c-avatar-small2-80x80.png) [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) 1. [](https://x.com/cooney_liz "X") 2. [](https://bsky.app/profile/elizabethcooney.bsky.social "Bluesky") 3. Cardiovascular Disease Reporter 1. [](https://x.com/cooney_liz "X") 2. [](https://bsky.app/profile/elizabethcooney.bsky.social "Bluesky") 3. Liz covers cardiovascular and metabolic disease, asking [why we’re not doing better](https://www.statnews.com/2024/10/15/cardiovascular-disease-rising-experts-on-causes/) or even [losing ground](https://www.statnews.com/2024/04/24/heart-failure-deaths-decline-undone/) against the world’s leading killer. Send tips on Signal at LizC.22. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/The-Readout-Logo-Black-640x99.png) ### Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_333549907-80x80.jpeg) [In parts of the world, antibiotic overuse isn’t the problem — underuse is](https://www.statnews.com/2026/08/18/antibiotic-underuse-overuse-resistance-aware/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2287497866-80x80.jpg) [Fauci doesn’t have the answers on Covid’s origins. China does](https://www.statnews.com/2026/08/07/fauci-contempt-congress-covid-origins-china/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/STAT-JustinDouglas-19-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [How health care costs are undermining America’s public-sector employers](https://www.statnews.com/2026/08/18/public-sector-employees-health-care-costs-out-of-pocket-series-part-4/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2289371420-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Kennedy’s split-screen week: Talk of vaccines in D.C., fraud and addiction out West](https://www.statnews.com/2026/08/17/rfk-jr-california-tour-maha-messaging-fight-fraud-addiction/) 5. ![](https://www.statnews.com/wp-content/uploads/2024/09/AdobeStock_138806370-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Eyepoint study results for vision treatment disappoint, but company still sees promise](https://www.statnews.com/2026/08/17/eyepoint-duravyu-wet-amd-study/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2025/08/VCFirms2025_LeftRailUnit-328x426.png) 2025 Edition: Ranking Biotech’s Top Venture Capital Firms ](https://reports.statnews.com/products/biotech-top-venture-capital-firms-2025) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/STAT_AIBillingSystem_F1_3000-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care](https://www.statnews.com/2026/08/12/inside-commure-athelas-mad-dash-automate-health-care/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/Schett-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies](https://www.statnews.com/2026/08/12/boulevard-bio-georg-schett-antibody-therapies/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_409379202_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [UnitedHealth faces IRS probe over potential tax avoidance](https://www.statnews.com/2026/08/17/unitedhealth-irs-probe-audit-targets-foreign-subsidiary-transfers/) 4. ![](https://www.statnews.com/wp-content/uploads/2022/12/AdobeStock_251916311-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class](https://www.statnews.com/2026/08/14/fda-approves-bristol-multiple-myeloma-drug-zenbexus/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_378516400-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say](https://www.statnews.com/2026/08/12/neurocrine-biosciences-vykat-prader-willi/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech August 17, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Eyepoint study results for vision treatment disappoint, but company still sees promise ](https://www.statnews.com/2026/08/17/eyepoint-duravyu-wet-amd-study/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout August 17, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit ](https://www.statnews.com/2026/08/17/biotech-news-akeso-summit-ivonescimabs-worsening-tumor-progression-benefit/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout August 14, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: PBMs agree to display TrumpRx drug prices ](https://www.statnews.com/2026/08/14/biotech-news-pbms-agree-to-display-trumprx-drug-prices/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech August 14, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class ](https://www.statnews.com/2026/08/14/fda-approves-bristol-multiple-myeloma-drug-zenbexus/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout August 13, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Eli Lilly targets booming black market for retatrutide ](https://www.statnews.com/2026/08/13/biotech-news-eli-lilly-targets-booming-retatrutide-black-market/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care ](https://www.statnews.com/2026/08/12/in
## Related Clinical Research

- [Moderna and Merck’s cancer vaccine algorithm: what’s known and why it matters](https://medichelpline.com/clinical-feed/stat-news-1-what-s-in-merck-and-moderna-s-cancer-vaccine-algorithm.md)
- [Massachusetts hospital CEOs saw large pay increases in 2024, Mass General Brigham CEO tops list](https://medichelpline.com/clinical-feed/stat-news-2-stat-leaders-of-mass-general-dana-farber-among-hospital-execs-who-got-big.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Sprint intervals boost heart-protective proteins more than moderate cycling, study finds](https://medichelpline.com/clinical-feed/medical-news-today-0-sprints-or-endurance-study-finds-short-workouts-release-heart-protective.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.